PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background & Aims: PARP1 is a key mediator of cellular stress responses and critical in multiple physiological and pathophysiological processes of cells. However, whether it is involved in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) remains elusive. Methods: We analysed PARP1 activity in the liver of mice on a high fat diet (HFD), and samples from NAFLD patients. Gain- or loss-of-function approaches were used to investigate the roles and mechanisms of hepatic PARP1 in the pathogenesis of NAFLD. Results: PARP1 is activated in fatty liver of HFD-fed mice. Pharmacological or genetic manipulations of PARP1 are sufficient to alter the HFD-induced hepatic steatosis and inflammation. Mechanistically we identified peroxisome proliferator-activated receptor α (PPARα) as a substrate of PARP1-mediated poly (ADP-ribosyl)ation. This poly(ADP-ribosyl)ation of PPARα inhibits its recruitment to target gene promoters and its interaction with SIRT1, a key regulator of PPARα signaling, resulting in suppression of fatty acid oxidation upregulation induced by fatty acids. Moreover, we show that PARP1 is a transcriptional repressor of PPARα gene in human hepatocytes, and its activation suppresses the ligand (fenofibrate)-induced PPARα transactivation and target gene expression. Importantly we demonstrate that liver biopsies of NAFLD patients display robust increases in PARP activity and PPARα poly(ADP-ribosyl)ation levels. Conclusions: Our data indicate that PARP1 is activated in fatty liver, which prevents maximal activation of fatty acid oxidation by suppressing PPARα signaling. Pharmacological inhibition of PARP1 may alleviate PPARα suppression and therefore have therapeutic potential for NAFLD. Lay summary: PARP1 is activated in the non-alcoholic fatty liver of mice and patients. Inhibition of PARP1 activation alleviates lipid accumulation and inflammation in fatty liver of mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772 · cited 1×
“Oxidative stress is an important mechanism contributing to the pathogenesis and propagation of inflammation in NAFLD[38].”
Mammalian sirtuins—emerging roles in physiology, aging, and calorie restriction
Haigis, M. C., & Guarente, L. P. (2006) · Genes & Development · doi:10.1101/gad.1467506 · Cited by 1,295 · cited 2×
“Under physiological conditions, SIRT1 deacetylates PGC-1α and associates with PPARα on target promoters to facilitate gene transcription[33].”
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · cited 1×
“In addition to triglycerides, lipotoxic lipids often accumulate in the fatty liver, leading to serious liver injuries through activation of oxidative stress, cell death and inflammatory responses [3], which may in turn worsen lipid metabolism deregulation, and create a vicious cycle to amplify liver damage and drive N…”
Hepatic inflammation and fibrosis: Functional links and key pathways
Seki, E., & Schwabe, R. F. (2015) · Hepatology · doi:10.1002/hep.27332 · Cited by 972
PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation
Bai, P., Cantó, C., Oudart, H., Brunyánszki, A., Cen, Y., Thomas, C., Yamamoto, H., Huber, A., Kiss, B., Houtkooper, R. H., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.03.004 · Cited by 837
Metabolic endotoxemia with obesity: Is it real and is it relevant?
Boutagy, N. E., McMillan, R. P., Frisard, M. I., & Hulver, M. W. (2016) · Biochimie · doi:10.1016/j.biochi.2015.06.020 · Cited by 413 · cited 1×
“In addition to triglycerides, lipotoxic lipids often accumulate in the fatty liver, leading to serious liver injuries through activation of oxidative stress, cell death and inflammatory responses [3], which may in turn worsen lipid metabolism deregulation, and create a vicious cycle to amplify liver damage and drive N…”
Pawlak, M., Baugé, E., Bourguet, W., De Bosscher, K., Lalloyer, F., Tailleux, A., Lebherz, C., Lefebvre, P., & Staels, B. (2014) · Hepatology · doi:10.1002/hep.27297 · Cited by 141 · cited 1×
“On the other hand, PPARα not only controls fatty acid oxidation, but also transrepresses pro-inflammatory signaling pathways through physical interaction with p65, c-Jun and C/EBP in the liver [41].”
Kohli, R., Pan, X., Malladi, P., Wainwright, M. S., & Whitington, P. F. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701759200 · Cited by 67 · cited 1×
“In addition to triglycerides, lipotoxic lipids often accumulate in the fatty liver, leading to serious liver injuries through activation of oxidative stress, cell death and inflammatory responses [3], which may in turn worsen lipid metabolism deregulation, and create a vicious cycle to amplify liver damage and drive N…”
Erener, S., Mirsaidi, A., Hesse, M., Tiaden, A. N., Ellingsgaard, H., Kostadinova, R., Donath, M. Y., Richards, P. J., & Hottiger, M. O. (2012) · The FASEB Journal · doi:10.1096/fj.11-200212 · Cited by 48
Cited by
Genetics and epigenetics of NAFLD and NASH: Clinical impact
Eslam, M., Valenti, L., & Romeo, S. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.003 · Cited by 971
Emerging roles of SIRT1 in fatty liver diseases
Ding, R.-B., Bao, J., & Deng, C.-X. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.19370 · Cited by 359
Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies
Wu, X., Xu, M., Geng, M., Chen, S., Little, P. J., Xu, S., & Weng, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01439-y · Cited by 272
The LPS-inducible lncRNA Mirt2 is a negative regulator of inflammation
Du, M., Yuan, L., Tan, X., Huang, D., Wang, X., Zheng, Z., Mao, X., Li, X., Yang, L., Huang, K., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02229-1 · Cited by 263
Self-citationTargeting NFATc4 attenuates non-alcoholic steatohepatitis in mice
Du, M., Wang, X., Yuan, L., Liu, B., Mao, X., Huang, D., Yang, L., Huang, K., Zhang, F., Wang, Y., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.030 · Cited by 41
Self-citation
Metadata
- Authors
- Huang, K., Du, M., Tan, X., Yang, L., Li, X., Jiang, Y., Wang, C., Zhang, F., Zhu, F., Cheng, M., Yang, Q., Yu, L., Wang, L., Huang, D., & Huang, K.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 66
- Issue
- 5
- Pages
- 962-977
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2564047037
- Cited by
- 102
- References
- 10
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease. https://app.cochat.ai/papers/10.1016/j.jhep.2016.11.020
- The paper
- Huang, K., Du, M., Tan, X., Yang, L., Li, X., Jiang, Y., Wang, C., Zhang, F., Zhu, F., Cheng, M., Yang, Q., Yu, L., Wang, L., Huang, D., & Huang, K. (2017). PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2016.11.020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.